Neuroimaging Spectrum of Inherited Neurotransmitter Disorders

 

 Buy Article Permissions and Reprints

Abstract

Inherited neurotransmitter disorders are rare neurometabolic conditions which encompass genetic disorders of neurotransmitter metabolism or transport. The clinical manifestations of these rare disorders are often nonspecific, ranging from encephalopathies and seizures to movement disorders. As a consequence, neurotransmitter disorders are underrecognized and often misdiagnosed. Accurate and timely diagnosis is, however, of utmost importance, given the availability of therapeutic strategies. A high index of clinical suspicion and familiarity with the neuroimaging phenotypes is therefore crucial. While the imaging features of various neurotransmitter disorders often overlap and are nonspecific, imaging can be helpful in providing useful clues to guide the diagnostic algorithm for uncommon conditions in a neonate presenting with nonspecific neurological symptoms. In this review paper, we aim to bring together current knowledge of neuroimaging phenotypes associated with inherited (primary) disorders of neurotransmitter biosynthesis. Magnetic resonance imaging phenotypes of disorders of monoamine biosynthesis, primary cerebral folate deficiency, disorders of pyridoxine metabolism, disorders of gamma-aminobutyric acid metabolism, nonketotic hyperglycinemia (glycine encephalopathy), disorders of serine biosynthesis, and cerebral creatine deficiency syndrome will be discussed and illustrated with case examples.

Financial Disclosure

The authors have no financial relationships relevant to this article to disclose.

• References

• 1 Brennenstuhl H, Jung-Klawitter S, Assmann B, Opladen T. Inherited disorders of neurotransmitters: classification and practical approaches for diagnosis and treatment. Neuropediatrics 2019; 50 (01) 2-14
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 Anikster Y, Haack TB, Vilboux T. , et al. Biallelic mutations in DNAJC12 cause hyperphenylalaninemia, dystonia, and intellectual disability. Am J Hum Genet 2017; 100 (02) 257-266
  CrossrefPubMedGoogle Scholar
• 3 Werner ER, Blau N, Thöny B. Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J 2011; 438 (03) 397-414
  CrossrefPubMedGoogle Scholar
• 4 Friedman J, Roze E, Abdenur JE. , et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol 2012; 71 (04) 520-530
  CrossrefPubMedGoogle Scholar
• 5 Brismar J, Aqeel A, Gascon G, Ozand P. Malignant hyperphenylalaninemia: CT and MR of the brain. AJNR Am J Neuroradiol 1990; 11 (01) 135-138
  PubMedGoogle Scholar
• 6 Pietz J, Meyding-Lamadé UK, Schmidt H. Magnetic resonance imaging of the brain in adolescents with phenylketonuria and in one case of 6-pyruvoyl tetrahydropteridine synthase deficiency. Eur J Pediatr 1996; 155 (Suppl. 01) S69-S73
  CrossrefPubMedGoogle Scholar
• 7 Elsayed SM, Thöny B. BH4 deficiency with unusual presentations: challenges and lessons. Egypt J Med Hum Genet 2016; 17 (03) 241-242 . Doi: 10.1016/j.ejmhg.2015.10.003
  CrossrefPubMedGoogle Scholar
• 8 Zhixin Z, Zhongshu Z, Weimin Y, Lin W, Xuezhe Z. MR study of the brain in patients with tetrahydrobiopterin deficiency. Chin J Radiol 2005; 39 (04) 399-402
  PubMedGoogle Scholar
• 9 Schmidt H, Ullrich K, Korinthenberg R, Peters PE. Basal ganglion calcification in hyperphenylalaninemia due to deficiency of dihydropteridine reductase. Pediatr Radiol 1988; 19 (01) 54-56
  CrossrefPubMedGoogle Scholar
• 10 Gudinchet F, Maeder P, Meuli RA, Deonna T, Mathieu JM. Cranial CT and MRI in malignant phenylketonuria. Pediatr Radiol 1992; 22 (03) 223-224
  CrossrefPubMedGoogle Scholar
• 11 Ramaekers VT, Blau N. Cerebral folate deficiency. Dev Med Child Neurol 2004; 46 (12) 843-851
  PubMedGoogle Scholar
• 12 Beckman DR, Hoganson G, Berlow S, Gilbert EF. Pathological findings in 5,10-methylene tetrahydrofolate reductase deficiency. Birth Defects Orig Artic Ser 1987; 23 (01) 47-64
  PubMedGoogle Scholar
• 13 Ramaekers V, Sequeira JM, Quadros EV. Clinical recognition and aspects of the cerebral folate deficiency syndromes. Clin Chem Lab Med 2013; 51 (03) 497-511
  PubMedGoogle Scholar
• 14 Hyland K, Shoffner J, Heales SJ. Cerebral folate deficiency. J Inherit Metab Dis 2010; 33 (05) 563-570
  CrossrefPubMedGoogle Scholar
• 15 Pérez-Dueñas B, Ormazábal A, Toma C. , et al. Cerebral folate deficiency syndromes in childhood: clinical, analytical, and etiologic aspects. Arch Neurol 2011; 68 (05) 615-621
  PubMedGoogle Scholar
• 16 Hansen FJ, Blau N. Cerebral folate deficiency: life-changing supplementation with folinic acid. Mol Genet Metab 2005; 84 (04) 371-373
  CrossrefPubMedGoogle Scholar
• 17 Frye RE, Sequeira JM, Quadros EV, James SJ, Rossignol DA. Cerebral folate receptor autoantibodies in autism spectrum disorder. Mol Psychiatry 2013; 18 (03) 369-381
  PubMedGoogle Scholar
• 18 Grapp M, Just IA, Linnankivi T. , et al. Molecular characterization of folate receptor 1 mutations delineates cerebral folate transport deficiency. Brain 2012; 135 (Pt 7): 2022-2031
  CrossrefPubMedGoogle Scholar
• 19 Kobayashi Y, Tohyama J, Akiyama T. , et al. Severe leukoencephalopathy with cortical involvement and peripheral neuropathy due to FOLR1 deficiency. Brain Dev 2017; 39 (03) 266-270
  CrossrefPubMedGoogle Scholar
• 20 Nicolai J, van Kempen MJA, Postma AA. Teaching neuroimages: white matter hypomyelination and progressive calcifications in cerebral folate deficiency. Neurology 2016; 87 (01) e4-e5
  CrossrefPubMedGoogle Scholar
• 21 van Karnebeek CDM, Tiebout SA, Niermeijer J. , et al. Pyridoxine-dependent epilepsy: an expanding clinical spectrum. Pediatr Neurol 2016; 59: 6-12
  CrossrefPubMedGoogle Scholar
• 22 Mills PB, Struys E, Jakobs C. , et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med 2006; 12 (03) 307-309
  CrossrefPubMedGoogle Scholar
• 23 van Karnebeek CDM, Jaggumantri S. Current treatment and management of pyridoxine-dependent epilepsy. Curr Treat Options Neurol 2015; 17 (02) 335
  PubMedGoogle Scholar
• 24 Stockler S, Plecko B, Gospe Jr SM. , et al. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab 2011; 104 (1-2): 48-60
  CrossrefPubMedGoogle Scholar
• 25 Gospe Jr SM, Hecht ST. Longitudinal MRI findings in pyridoxine-dependent seizures. Neurology 1998; 51 (01) 74-78
  CrossrefPubMedGoogle Scholar
• 26 Tanaka R, Okumura M, Arima J, Yamakura S, Momoi T. Pyridoxine-dependent seizures: report of a case with atypical clinical features and abnormal MRI scans. J Child Neurol 1992; 7 (01) 24-28
  CrossrefPubMedGoogle Scholar
• 27 Ulvi H, Müngen B, Yakinci C, Yoldaş T. Pyridoxine-dependent seizures: long-term follow-up of two cases with clinical and MRI findings, and pyridoxine treatment. J Trop Pediatr 2002; 48 (05) 303-306
  CrossrefPubMedGoogle Scholar
• 28 Jain-Ghai S, Mishra N, Hahn C, Blaser S, Mercimek-Mahmutoglu S. Fetal onset ventriculomegaly and subependymal cysts in a pyridoxine dependent epilepsy patient. Pediatrics 2014; 133 (04) e1092-e1096
  CrossrefPubMedGoogle Scholar
• 29 Baxter P, Griffiths P, Kelly T, Gardner-Medwin D. Pyridoxine-dependent seizures: demographic, clinical, MRI and psychometric features, and effect of dose on intelligence quotient. Dev Med Child Neurol 1996; 38 (11) 998-1006
  PubMedGoogle Scholar
• 30 Marguet F, Barakizou H, Tebani A. , et al. Pyridoxine-dependent epilepsy: report on three families with neuropathology. Metab Brain Dis 2016; 31 (06) 1435-1443
  CrossrefPubMedGoogle Scholar
• 31 Mills PB, Footitt EJ, Mills KA. , et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain 2010; 133 (Pt 7): 2148-2159
  CrossrefPubMedGoogle Scholar
• 32 Pérez B, Gutiérrez-Solana LG, Verdú A. , et al. Clinical, biochemical, and molecular studies in pyridoxine-dependent epilepsy. Antisense therapy as possible new therapeutic option. Epilepsia 2013; 54 (02) 239-248
  CrossrefPubMedGoogle Scholar
• 33 Friedman SD, Ishak GE, Poliachik SL. , et al. Callosal alterations in pyridoxine-dependent epilepsy. Dev Med Child Neurol 2014; 56 (11) 1106-1110
  CrossrefPubMedGoogle Scholar
• 34 Jansen LA, Hevner RF, Roden WH, Hahn SH, Jung S, Gospe Jr SM. Glial localization of antiquitin: implications for pyridoxine-dependent epilepsy. Ann Neurol 2014; 75 (01) 22-32
  CrossrefPubMedGoogle Scholar
• 35 Kriegstein A, Alvarez-Buylla A. The glial nature of embryonic and adult neural stem cells. Annu Rev Neurosci 2009; 32: 149-184
  CrossrefPubMedGoogle Scholar
• 36 Lado FA, Laureta EC, Moshé SL. Seizure-induced hippocampal damage in the mature and immature brain. Epileptic Disord 2002; 4 (02) 83-97
  PubMedGoogle Scholar
• 37 Darin N, Reid E, Prunetti L. , et al. Mutations in PROSC disrupt cellular pyridoxal phosphate homeostasis and cause vitamin-B₆-dependent epilepsy. Am J Hum Genet 2016; 99 (06) 1325-1337
  CrossrefPubMedGoogle Scholar
• 38 Plecko B, Zweier M, Begemann A. , et al. Confirmation of mutations in PROSC as a novel cause of vitamin B ₆ -dependent epilepsy. J Med Genet 2017; 54 (12) 809-814
  CrossrefPubMedGoogle Scholar
• 39 Johnstone DL, Al-Shekaili HH, Tarailo-Graovac M. , et al; Care4Rare Canada Consortium. PLPHP deficiency: clinical, genetic, biochemical, and mechanistic insights. Brain 2019; 142 (03) 542-559
  CrossrefPubMedGoogle Scholar
• 40 Kanno K, Suzuki Y, Yamada A, Aoki Y, Kure S, Matsubara Y. Association between nonsyndromic cleft lip with or without cleft palate and the glutamic acid decarboxylase 67 gene in the Japanese population. Am J Med Genet A 2004; 127A (01) 11-16
  CrossrefPubMedGoogle Scholar
• 41 Parviz M, Vogel K, Gibson KM, Pearl PL. Disorders of GABA metabolism: SSADH and GABA-transaminase deficiencies. J Pediatr Epilepsy 2014; 3 (04) 217-227
  Article in Thieme ConnectPubMedGoogle Scholar
• 42 Pearl PL, Parviz M, Vogel K, Schreiber J, Theodore WH, Gibson KM. Inherited disorders of gamma-aminobutyric acid metabolism and advances in ALDH5A1 mutation identification. Dev Med Child Neurol 2015; 57 (07) 611-617
  CrossrefPubMedGoogle Scholar
• 43 Jung R, Rauch A, Salomons GS. , et al. Clinical, cytogenetic and molecular characterization of a patient with combined succinic semialdehyde dehydrogenase deficiency and incomplete WAGR syndrome with obesity. Mol Genet Metab 2006; 88 (03) 256-260
  CrossrefPubMedGoogle Scholar
• 44 Pearl PL, Gibson KM, Acosta MT. , et al. Clinical spectrum of succinic semialdehyde dehydrogenase deficiency. Neurology 2003; 60 (09) 1413-1417
  CrossrefPubMedGoogle Scholar
• 45 Jaeken J, Casaer P, de Cock P. , et al. Gamma-aminobutyric acid-transaminase deficiency: a newly recognized inborn error of neurotransmitter metabolism. Neuropediatrics 1984; 15 (03) 165-169
  Article in Thieme ConnectPubMedGoogle Scholar
• 46 Tsuji M, Aida N, Obata T. , et al. A new case of GABA transaminase deficiency facilitated by proton MR spectroscopy. J Inherit Metab Dis 2010; 33 (01) 85-90
  CrossrefPubMedGoogle Scholar
• 47 Besse A, Wu P, Bruni F. , et al. The GABA transaminase, ABAT, is essential for mitochondrial nucleoside metabolism. Cell Metab 2015; 21 (03) 417-427
  CrossrefPubMedGoogle Scholar
• 48 Louro P, Ramos L, Robalo C. , et al. Phenotyping GABA transaminase deficiency: a case description and literature review. J Inherit Metab Dis 2016; 39 (05) 743-747
  CrossrefPubMedGoogle Scholar
• 49 Moura AP, Parmeggiani B, Gasparotto J. , et al. Glycine administration alters MAPK signaling pathways and causes neuronal damage in rat brain: putative mechanisms involved in the neurological dysfunction in nonketotic hyperglycinemia. Mol Neurobiol 2018; 55 (01) 741-750
  CrossrefPubMedGoogle Scholar
• 50 Belcastro V, Barbarini M, Barca S, Mauro I. A novel AMT gene mutation in a newborn with nonketotic hyperglycinemia and early myoclonic encephalopathy. Eur J Paediatr Neurol 2016; 20 (01) 192-195
  CrossrefPubMedGoogle Scholar
• 51 Korman SH, Gutman A. Pitfalls in the diagnosis of glycine encephalopathy (non-ketotic hyperglycinemia). Dev Med Child Neurol 2002; 44 (10) 712-720
  PubMedGoogle Scholar
• 52 Ichinohe A, Kure S, Mikawa S. , et al. Glycine cleavage system in neurogenic regions. Eur J Neurosci 2004; 19 (09) 2365-2370
  CrossrefPubMedGoogle Scholar
• 53 Van Hove J, Coughlin C, Scharer G. Glycine encephalopathy. In: Adam MP, Ardinger HH, Pagon RA. , et al., eds. GeneReviews®. Seattle, WA: University of Washington; 1993
  Google Scholar
• 54 Dinopoulos A, Matsubara Y, Kure S. Atypical variants of nonketotic hyperglycinemia. Mol Genet Metab 2005; 86 (1-2): 61-69
  PubMedGoogle Scholar
• 55 Hennermann JB, Berger J-M, Grieben U, Scharer G, Van Hove JLK. Prediction of long-term outcome in glycine encephalopathy: a clinical survey. J Inherit Metab Dis 2012; 35 (02) 253-261
  CrossrefPubMedGoogle Scholar
• 56 Iqbal M, Prasad M, Mordekar SR. Nonketotic hyperglycinemia case series. J Pediatr Neurosci 2015; 10 (04) 355-358
  CrossrefPubMedGoogle Scholar
• 57 Aliefendioğlu D, Tana Aslan Ay, Coşkun T, Dursun A, Cakmak FN, Kesimer M. Transient nonketotic hyperglycinemia: two case reports and literature review. Pediatr Neurol 2003; 28 (02) 151-155
  CrossrefPubMedGoogle Scholar
• 58 Zammarchi E, Donati MA, Ciani F. Transient neonatal nonketotic hyperglycinemia: a 13-year follow-up. Neuropediatrics 1995; 26 (06) 328-330
  Article in Thieme ConnectPubMedGoogle Scholar
• 59 Mourmans J, Majoie CBLM, Barth PG, Duran M, Akkerman EM, Poll-The BT. Sequential MR imaging changes in nonketotic hyperglycinemia. AJNR Am J Neuroradiol 2006; 27 (01) 208-211
  PubMedGoogle Scholar
• 60 Raghavendra S, Ashalatha R, Thomas SV, Kesavadas C. Focal neuronal loss, reversible subcortical focal T2 hypointensity in seizures with a nonketotic hyperglycemic hyperosmolar state. Neuroradiology 2007; 49 (04) 299-305
  CrossrefPubMedGoogle Scholar
• 61 Langan TJ, Pueschel SM. Nonketotic hyperglycinemia: clinical, biochemical, and therapeutic considerations. Curr Probl Pediatr 1983; 13 (03) 1-30
  PubMedGoogle Scholar
• 62 Paupe A, Bidat L, Sonigo P, Lenclen R, Molho M, Ville Y. Prenatal diagnosis of hypoplasia of the corpus callosum in association with non-ketotic hyperglycinemia. Ultrasound Obstet Gynecol 2002; 20 (06) 616-619
  CrossrefPubMedGoogle Scholar
• 63 Mohammad SA, Abdelkhalek HS. Nonketotic hyperglycinemia: spectrum of imaging findings with emphasis on diffusion-weighted imaging. Neuroradiology 2017; 59 (11) 1155-1163
  CrossrefPubMedGoogle Scholar
• 64 Dobyns WB. Agenesis of the corpus callosum and gyral malformations are frequent manifestations of nonketotic hyperglycinemia. Neurology 1989; 39 (06) 817-820
  CrossrefPubMedGoogle Scholar
• 65 Bekiesiñiska-Figatowska M, Rokicki D, Walecki J. MRI in nonketotic hyperglycinaemia: case report. Neuroradiology 2001; 43 (09) 792-793
  CrossrefPubMedGoogle Scholar
• 66 Manel L, Houneida ZBA, Habib A, Dejla B, Chekib K. A rare inborn error of metabolism associated with a Dandy-Walker malformation. Acta Neurol Belg 2012; 112 (04) 425-426
  CrossrefPubMedGoogle Scholar
• 67 Van Hove JL, Kishnani PS, Demaerel P. , et al. Acute hydrocephalus in nonketotic hyperglycinemia. Neurology 2000; 54 (03) 754-756
  CrossrefPubMedGoogle Scholar
• 68 Khong P-L, Lam BCC, Chung BHY, Wong K-Y, Ooi G-C. Diffusion-weighted MR imaging in neonatal nonketotic hyperglycinemia. AJNR Am J Neuroradiol 2003; 24 (06) 1181-1183
  PubMedGoogle Scholar
• 69 Kanekar S, Byler D. Characteristic MRI findings in neonatal nonketotic hyperglycinemia due to sequence changes in GLDC gene encoding the enzyme glycine decarboxylase. Metab Brain Dis 2013; 28 (04) 717-720
  CrossrefPubMedGoogle Scholar
• 70 Nicolasjilwan M, Ozer H, Wintermark M, Matsumoto J. Neonatal non-ketotic hyperglycinemia. J Neuroradiol 2011; 38 (04) 246-250
  CrossrefPubMedGoogle Scholar
• 71 Sener RN. Nonketotic hyperglycinemia: diffusion magnetic resonance imaging findings. J Comput Assist Tomogr 2003; 27 (04) 538-540
  CrossrefPubMedGoogle Scholar
• 72 Huisman TAGM, Thiel T, Steinmann B, Zeilinger G, Martin E. Proton magnetic resonance spectroscopy of the brain of a neonate with nonketotic hyperglycinemia: in vivo-in vitro (ex vivo) correlation. Eur Radiol 2002; 12 (04) 858-861
  CrossrefPubMedGoogle Scholar
• 73 Fons C, Campistol J. Creatine defects and central nervous system. Semin Pediatr Neurol 2016; 23 (04) 285-289
  CrossrefPubMedGoogle Scholar
• 74 Pasquali M, Schwarz E, Jensen M. , et al. Feasibility of newborn screening for guanidinoacetate methyltransferase (GAMT) deficiency. J Inherit Metab Dis 2014; 37 (02) 231-236
  CrossrefPubMedGoogle Scholar
• 75 Clark JF, Cecil KM. Diagnostic methods and recommendations for the cerebral creatine deficiency syndromes. Pediatr Res 2015; 77 (03) 398-405
  CrossrefPubMedGoogle Scholar
• 76 Stockler-Ipsiroglu S, van Karnebeek C, Longo N. , et al. Guanidinoacetate methyltransferase (GAMT) deficiency: outcomes in 48 individuals and recommendations for diagnosis, treatment and monitoring. Mol Genet Metab 2014; 111 (01) 16-25
  CrossrefPubMedGoogle Scholar
• 77 Póo-Argüelles P, Arias A, Vilaseca MA. , et al. X-Linked creatine transporter deficiency in two patients with severe mental retardation and autism. J Inherit Metab Dis 2006; 29 (01) 220-223
  CrossrefPubMedGoogle Scholar
• 78 Mancini GMS, Catsman-Berrevoets CE, de Coo IFM. , et al. Two novel mutations in SLC6A8 cause creatine transporter defect and distinctive X-linked mental retardation in two unrelated Dutch families. Am J Med Genet A 2005; 132A (03) 288-295
  CrossrefPubMedGoogle Scholar
• 79 Poretti A, Blaser SI, Lequin MH. , et al. Neonatal neuroimaging findings in inborn errors of metabolism. J Magn Reson Imaging 2013; 37 (02) 294-312
  CrossrefPubMedGoogle Scholar
• 80 Manning MA, Cunniff CM, Colby CE, El-Sayed YY, Hoyme HE. Neu-Laxova syndrome: detailed prenatal diagnostic and post-mortem findings and literature review. Am J Med Genet A 2004; 125A (03) 240-249
  CrossrefPubMedGoogle Scholar
• 81 Badakali M, Badakali A, Dombale V. Rare manifestations of Neu-Laxova syndrome. Fetal Pediatr Pathol 2012; 31 (01) 1-5
  CrossrefPubMedGoogle Scholar
• 82 El-Hattab AW. Serine biosynthesis and transport defects. Mol Genet Metab 2016; 118 (03) 153-159
  CrossrefPubMedGoogle Scholar
• 83 Damseh N, Simonin A, Jalas C. , et al. Mutations in SLC1A4, encoding the brain serine transporter, are associated with developmental delay, microcephaly and hypomyelination. J Med Genet 2015; 52 (08) 541-547
  CrossrefPubMedGoogle Scholar